Ikena Oncology, Inc. (IKNA) Dividend History

Ikena Oncology, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer. It utilizes its proprietary platform to identify and develop treatments aimed at genetic and molecular drivers of cancer, with a focus on precision medicine approaches to improve patient outcomes.

50 Northern Ave., Boston, MA, 02210
Phone: 857-343-8292
Website: https://www.ikenaoncology.com

Dividend History

Ikena Oncology, Inc. currently does not pay dividends

Company News

Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals

Ikena Oncology shareholders approved a merger with Inmagene Biopharmaceuticals, with plans to rename the company ImageneBio and trade under ticker 'IMA'. The merger will be accompanied by a 1-for-12 reverse stock split, reducing outstanding shares from 48.2 million to approximately 4 million.

Benzinga
UPDATE – Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930

GlobeNewswire Inc.
Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Ikena Oncology, Inc. (IKNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research

Page data last updated 07/23/2025 22:17:38 UTC